Tag:
Zymeworks
Latest Headlines
Latest Headlines
Merck taps Zymeworks' high-tech antibody shop in $187M deal
Drug giant Merck's ( $MRK ) latest collaboration gives developer Zymeworks a nice plug for its high-tech approach to discovering bi-specific antibodies that can bind to two different drug targets with
Zymeworks inks $187M Merck deal on bi-specific antibodies
Vancouver-based Zymeworks has struck a deal to put its platform technology to work developing bi-specific antibodies for Merck. The biotech gets an unspecified upfront payment, $187 million in
